Despite its benefits, the Clinical Trials Directive has been criticized for potentially slowing down the initiation of trials due to its rigorous regulatory requirements. Some researchers argue that the complexity of the application process can lead to increased costs and delays. However, these challenges are often outweighed by the benefits of ensuring participant safety and data quality.
